Concerned about your investment in ElectroCore Inc. (ECOR)? 

Investigating Potential Claims involving ElectroCore Inc. 

Are you concerned about investment losses in ElectroCore Inc. (ECOR)? If so, the securities attorneys at The White Law Group may be able to help you recoup your losses by filing a FINRA Arbitration claim against the brokerage firm that sold you the investment.  

ElectroCore, Inc., a biotech company, reportedly develops a platform bioelectronic medical therapy that modulates neurotransmitters and immune function through its effects on both the peripheral and central nervous systems.  

The company reportedly went public in June 2018 with a $78 million IPO, listing 5.2 million shares of common stock at $15.00 per share. According to MarketWatch on September 1, the ECOR stock closed at $1.05 per share. 

The problem with pharmaceutical and biotech investments is that they typically involve a high degree of risk. The research and development process for pharma companies often involves costly and lengthy testing trials that yield specific data. If the expected data or end points are not met, that could be bad news for investors. 

Broker dealers are required to perform adequate due diligence on any investment they recommend and to ensure that all recommendations are suitable for the investor. Recommendations should be in line with the investor’s age, risk tolerance, net worth, and investment experience.  

If you lost money investing in ElectroCore Inc. and would like to speak with a securities attorney about your options, please call The White Law Group at 888-637-5510 for a free consultation.  

The White Law Group is a national securities fraud, securities arbitration, and investor protection law firm with offices in Chicago, Illinois.  

For more information on The White Law Group and its representation of investors in FINRA arbitration claims, visit?https://whitesecuritieslaw.com.